Safety pharmacology is a critical component of the drug discovery process, as it helps to identify potential side effects on cognitive functions of drugs entering the Central Nervous System early on in development. This allows for necessary adjustments to be made before the drug enters clinical trials, reducing the chances of costly and time-consuming delays or setbacks.
Evaluating the CNS Safety of drugs is essential to ensure that they are safe and effective for human use. Additionally, the FDA and other regulatory bodies require thorough evaluation of CNS Safety as part of the drug approval process. It is therefore crucial that drug development teams prioritize and incorporate CNS Safety pharmacology evaluations early on in the drug discovery process.